Dr Reddys Laboratories Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Solid FY24, Q4 dip is noise: Underlying YoY revenue grew 17% (adjusted for brand divestment), but Q4 saw a sequential decline driven by normal ordering patterns for Lenalidomide and base-business price erosion, not market share loss.
• R&D spend is stepping up structurally: R&D hit 8.5% to 9% of revenue, a new guided baseline, as the pipeline shifts toward complex small molecules and biosimilars that will contribute meaningfully only from FY25–FY28.
• India is the declared growth engine: A long-term revenue target of Rs. 12,000 crores by FY30 is anchored on branded generics, new innovative launches, and the Nestlé JV, though the JV’s contribution is post-FY27 at the earliest.
• Margins are healthy but unguided: Gross margin improved 140 bps YoY on mix and productivity; management declined to give FY25 EBITDA guidance but noted the long-term target is 25% EBITDA with 25% ROCE.
• What to watch next quarter: The pace of the ~20 planned US product launches, resolution of the Rituximab CRL (response planned around September), and any update on the Liraglutide opportunity timing.

US Business: The Lenalidomide Overhang

• Sequential decline explained: The Q4 drop is a combination of the normal ordering pattern for Lenalidomide and price erosion on a few base-business products, not a loss of market share. Management called it a sequence-of-supply issue.
• Price erosion reality: The company faced competition in some big products and saw price erosion, but this was partially compensated by growth in other products. The overall sentiment on the US business remains unchanged, with the lion’s share of interest being sustainability of service and supply.
• gRevlimid sustainability: Management expects the product to remain meaningful throughout the period of the agreement but refused to discuss quantities, pricing trends, or the impact of new entrants, citing confidentiality.
• Launch pipeline: Five products were launched in the US during Q4, and about twenty-plus launches are planned for FY25. Generic Lumify, approved this quarter, is expected to launch in Q1 FY25.

Israeli: "I am not going to discuss quantities or prices of this product. We need to remain confidential to our agreements."

India: The Growth Leader

• Long-term ambition: India is positioned as the growth leader for the company over the next few years, with a neighborhood target of Rs. 12,000 crores in revenue somewhere in FY30.
• Growth drivers: The branded generics business will continue to grow, supplemented by new launches like Nerivio and other innovative products. India is also the main hub for innovation and the primary market where collaborators want to leverage Dr. Reddy’s go-to-market capabilities. [15-16]
• Nestlé JV mechanics: The joint venture will bring Nestlé Health Science brands into India using Dr. Reddy’s commercial infrastructure. The first couple of years will be investment years as products are brought in, registered, and adjusted to Indian regulatory and taste requirements. Contribution to India business will be post-FY26, likely even post-FY27, and will be over and above double-digit growth.
• Branded generics moat: Management sees no imminent danger of commoditization by generic-generics, citing enforcement gaps in quality and doctors’ quality concerns that have caused several prior attempts at a pure generic-generic model to fail.
• Organized pharmacy exposure: Organized pharmacies remain a small portion of overall sales, in the 12% to 15% range at most.

Prasad: "We don't see any imminent danger of it being commoditized by generic-generics."

Pipeline & R&D: The Long Bet

• R&D spend trajectory: Q4 R&D was up 28% YoY and 24% QoQ, driven by biosimilar product development, complex generics, and novel oncology assets in Aurigene. Full-year R&D grew 18%. Management guided to a sustainable 8.5% to 9% of revenue going forward, with fluctuations depending on Phase III timing.
• Small molecule contribution timeline: The pipeline will begin contributing to growth in FY25, with more in FY26, and some assets in FY27-28.
• Biosimilar contribution timeline: Internal biosimilar products are likely to start contributing around FY27. The strategy is to skip products where the company would be late to market and to develop globally for the US, Europe, India, and Emerging Markets.
• Rituximab setback: The USFDA issued a Complete Response Letter for the biosimilar Rituximab BLA, with questions primarily around CMC. Management plans to address these around September, assuming a six-month goal date thereafter. A UK launch is planned and expected to receive approval soon, pending an EMA inspection.
• Liraglutide opportunity: The company is putting efforts into both API and finished goods and plans to be present in each market. Management has launch dates for Victoza and Saxenda but declined to share them, stating only that they will launch when the market is open.

Israeli: "We believe that it is sustainable for us to be in, what I said 8.5% to 9%, and it could be some fluctuation depends on the timing of the Phase III of the products."

Partnerships & Portfolio Moves

• Nestlé JV: A joint venture to bring nutraceuticals to Indian consumers, leveraging Nestlé Health Science brands and Dr. Reddy’s commercial capabilities. Both parties are contributing their current nutraceutical portfolios through the JV.
• Sanofi vaccine partnership: An exclusive partnership to market and distribute Sanofi’s vaccine brands in India, taking Dr. Reddy’s to the second position among vaccine players in the country.
• Bayer partnership: A partnership for the second brand of Vericiguat, a new class of drug for heart failure management in India.
• Amgen collaboration: An agreement to bring romosozumab injection (Evenity) to India for osteoporosis in post-menopausal women at high risk of fracture.
• MenoLabs acquisition: Acquired a portfolio of women’s dietary supplement brands from Amyris, Inc. for the self-care and wellness business in the US.
• UK consumer health entry: Launched the allergy medication Histallay, marking entry into the UK consumer health market.
• Celevida Wellness wind-down: The pilot direct-to-consumer e-commerce website for diabetes nutrition is being wound down to repurpose resources.

Financials & Capital Allocation

• Gross margin improvement: Q4 gross margin was up 140 bps YoY, driven by product mix improvement and productivity-linked cost savings, partially offset by brand divestment income in the prior period.
• SG&A in line: Full-year SG&A grew 13%, largely in line with business growth, and stood at 27.7% of sales, the same as last year. Management expects this ratio to remain in a similar range over the next 12 months.
• R&D and other income: Q4 R&D was up 28% YoY, while other operating income declined due to a one-time settlement in the previous year. The effective tax rate was lower in Q4 due to a one-time benefit from reversal of a tax provision and adoption of the corporate tax rate under section 115BAA.
• Capex priorities: More than 50% of capex is directed toward products to be launched and creating capacity in API and injectable facilities. Additional capacity is being built in the biologics plant in Bachupally and in APSL services. Overall, 75% of capex goes to expansion.
• Inventory build: Inventory increased proactively to mitigate geopolitical risks impacting supply routes and to ensure no loss of sales.
• Capital allocation: The number one priority remains reinvesting in the business, including the pipeline and building businesses of the future. The company is committed to pursuing value-enhancing business development transactions to augment organic growth.

Regulatory & Operational Updates

• Bachupally VAI status: The USFDA provided Voluntary Action Indicated status to two Hyderabad facilities: the formulations manufacturing facility FTO-3 and the R&D facility, following inspections in late 2023.
• Rituximab CRL: The Complete Response Letter for the BLA pertains to CMC questions and has no impact on the development or manufacturing of any current or pipeline product.
• ESG recognition: Included in the S&P Global Sustainability Yearbook 2024 for the fourth consecutive year, achieving a top 10% score for the first time. Received an ‘A’ rating in CDP Supplier Engagement and is the only Indian pharma company with an ‘A minus’ rating in both Climate Change and Water Security.
• India manufacturing: About 60% of India business products are manufactured in-house, and this number is likely to increase due to localization of some products.

Guidance & Commitments

Key Metrics